Autologous Infusion of Expanded Mobilized Adult Bone Marrow-Derived CD34+ Cells Into Patients With Alcoholic Liver Cirrhosis

Pai, Madhava; Zacharoulis, Dimitris; Milicevic, Miroslav N.; Helmy, Salah; Jiao, Long R.; Levičar, Nataša; Tait, Paul; Scott, Michael; Marley, Stephen B.; Jestice, Kevin; Glibetic, Maria; Bansi, Devinder; Khan, Shahid A.; Kyriakou, Despina; Rountas, Christos; Thillainayagam, Andrew; Nicholls, Joanna P.; Jensen, Steen; Apperley, Jane F.; Gordon, Myrtle Y.
August 2008
American Journal of Gastroenterology;Aug2008, Vol. 103 Issue 8, p1952
Academic Journal
OBJECTIVES: Recent advances in regenerative medicine, including hematopoietic stem cell (HSC) transplantation, have brought hope for patients with severe alcoholic liver cirrhosis (ALC). The aim of this study was to assess the safety and efficacy of administering autologous expanded mobilized adult progenitor CD34+ cells into the hepatic artery of ALC patients and the potential improvement in the liver function. METHODS: Nine patients with biopsy-proven ALC, who had abstained from alcohol for at least 6 months, were recruited into the study. Following granulocyte colony-stimulating factor (G-CSF) mobilization and leukapheresis, the autologous CD34+ cells were expanded in vitro and injected into the hepatic artery. All patients were monitored for side effects, toxicities, and changes in the clinical, hematological, and biochemical parameters. RESULTS: On average, a five-fold expansion in cell number was achieved in vitro, with a mean total nucleated cell count (TNCC) of 2.3 × 108 pre infusion. All patients tolerated the procedure well, and there were no treatment-related side effects or toxicities observed. There were significant decreases in serum bilirubin ( P < 0.05) 4, 8, and 12 wk post infusion. The levels of alanine transaminase (ALT) and aspartate transaminase (AST) showed improvement through the study period and were significant ( P < 0.05) 1 wk post infusion. The Child-Pugh score improved in 7 out of 9 patients, while 5 patients had improvement in ascites on imaging. CONCLUSION: It is safe to mobilize, expand, and reinfuse autologous CD34+ cells in patients with ALC. The clinical and biochemical improvement in the study group is encouraging and warrants further clinical trials.


Related Articles

  • Hematopoietic stem cell transplantation activity in Europe 1999. Gratwohl, A; Passweg, J; Baldomero, H; Urbano-Ispizua, A // Bone Marrow Transplantation;5/1/2001, Vol. 27 Issue 9, p899 

    This survey on transplantation of hematopoietic stem cells from blood or bone marrow in Europe, the 10th in a series, reports the numbers of transplants performed in 1999 and concentrates on changes in indications and donor types. Members of the European Group for Blood and Marrow...

  • Hematopoietic stem cell transplantation for autoimmune diseases in developing countries: current status and future prospectives. Voltarelli, J C; Ouyang, J // Bone Marrow Transplantation;Aug2003 Supplement 1, Vol. 32 Issue 1, pS69 

    Summary:In this paper we present preliminary results of hematopoietic stem cell transplantation for autoimmune diseases in Brazil and China. Chinese experience transplanting lupus is significant and the Brazilian experience with several autoimmune diseases is growing. We discuss peculiar...

  • Autologous hematopoietic stem cell transplantation for autoimmune diseases. Gratwohl, A; Passweg, J; Bocelli-Tyndall, C; Fassas, A; van Laar, J M; Farge, D; Andolina, M; Arnold, R; Carreras, E; Finke, J; Kötter, I; Kozak, T; Lisukov, I; Löwenberg, B; Marmont, A; Moore, J; Saccardi, R; Snowden, J A; van den Hoogen, F; Wulffraat, N M // Bone Marrow Transplantation;May2005, Vol. 35 Issue 9, p869 

    Summary:Experimental data and early phase I/II studies suggest that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) can arrest progression of severe autoimmune diseases. We have evaluated the toxicity and disease response in 473 patients with severe...

  • Unrelated hematopoietic stem cell donors as research subjects. King, R. J.; Confer, D. L.; Greinix, H. T.; Halter, J.; Horowitz, M.; Schmidt, A. H.; Costeas, P.; Shaw, B.; Egeland, T. // Bone Marrow Transplantation;Jan2011, Vol. 46 Issue 1, p10 

    Requests for participation of unrelated stem cell donors in research transplant protocols are becoming more frequent. World Marrow Donor Association calls on donor registries to participate in research activities. Here, we discuss various implications of research participation and make some...

  • Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Niscola, P.; Romani, C.; Scaramucci, L.; Dentamaro, T.; Cupelli, L.; Tendas, A.; Piccioni, D.; Giovannini, M.; Tolu, B.; Cartoni, C.; Arcuri, E.; Perrotti, A.; Palumbo, R.; de Fabritiis, P. // Bone Marrow Transplantation;May2008, Vol. 41 Issue 9, p757 

    Severe pain syndromes may be recorded during all phases of haematopoietic stem cell transplantation (HSCT) for haematological malignancies: from stem cell mobilization to the long-term post transplant period. Although the major cause of pain in the setting of HSCT is injury to mucosal tissues...

  • Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis. Woodard, P.; Helton, K.; McDaniel, H.; Khan, R. B.; Thompson, S.; Hale, G.; Benaim, E.; Kasow, K.; Leung, W.; Horwitz, E.; Srivastava, D. K.; Tong, X.; Yusuf, U.; Cunningham, J. M.; Handgretinger, R. // Bone Marrow Transplantation;Jun2004, Vol. 33 Issue 11, p1151 

    Encephalopathy is a poorly characterized complication of hematopoietic stem cell transplantation (HSCT). No comprehensive report of encephalopathy exists for children, and the literature contains only a few for adults. We analyzed a large cohort of 405 pediatric patients who underwent allogeneic...

  • Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Chunduri, S.; Dobogai, L. C.; Peace, D.; Saunthararajah, Y.; Quigley, J.; Chen, Y.-H.; Mahmud, N.; Hurter, E.; Beri, R.; Rondelli, D. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p935 

    In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18�61) with myeloid or lymphoid malignancies at standard risk (n=10) or high risk of relapse (n=26), who received an...

  • Management strategies for the hard-to-mobilize patient. Stiff, Patrick J. // Bone Marrow Transplantation;5/1/99 Supplement 2, Vol. 23, pS29 

    Delayed hematopoietic engraftment, particularly of platelets, is seen in 5–35% of patients undergoing high-dose chemotherapy with autologous stem cell transplantation. Studies indicate that delayed engraftment is related to low CD34+ cell dose, and that risk factors for poor mobilization...

  • Comorbidity and beyond: pre-transplant clinical assessment. Artz, A. S. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p473 

    Investigates the use of comorbidity scales that provide relative weights to nondisease-related medical conditions as predictors of hematopoietic stem cell transplantation outcomes. Importance of pre-transplant comorbidity assessment; Efficacy of this method compared to single organ comorbidity...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics